Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
McKinsey
Harvard Business School
AstraZeneca
Boehringer Ingelheim

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR OLEPTRO

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Oleptro

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00253890 Insomnia and Drug Relapse Risk Completed National Institute on Drug Abuse (NIDA) Phase 3 2005-10-01 The purposes of this study are: 1. to evaluate the relationship between subjective complaints of sleep and objective measures of sleep quality, as measured through polysomnography, and 2. to evaluate the efficacy of trazodone, as compared to placebo, in individuals early in methadone maintenance.
NCT00253890 Insomnia and Drug Relapse Risk Completed Butler Hospital Phase 3 2005-10-01 The purposes of this study are: 1. to evaluate the relationship between subjective complaints of sleep and objective measures of sleep quality, as measured through polysomnography, and 2. to evaluate the efficacy of trazodone, as compared to placebo, in individuals early in methadone maintenance.
NCT00775203 A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder. Completed Labopharm Inc. Phase 3 2007-06-01 The purpose of this study was to demonstrate efficacy, safety and clinical benefit of Trazodone Contramid® OAD (Once A Day) in the treatment of Unipolar Major Depressive Disorder (MDD).
NCT00839072 Comparative Bioavailability Study of Extended-release and Immediate-release Trazodone in Healthy Adult Volunteers Completed Algorithme Pharma Inc Phase 1 2009-02-01 The objective of the study is to compare the pharmacokinetic profiles of extended-release and immediate-release trazodone formulations
NCT00839072 Comparative Bioavailability Study of Extended-release and Immediate-release Trazodone in Healthy Adult Volunteers Completed Labopharm Inc. Phase 1 2009-02-01 The objective of the study is to compare the pharmacokinetic profiles of extended-release and immediate-release trazodone formulations
NCT01121900 A Study to Compare the Bioavailability of 300 mg Trazodone Hydrochloride Extended-release Caplets and 100 mg Trazodone Hydrochloride Immediate-release Tablets (Administered Three Times Daily) Completed Labopharm Inc. Phase 1 2008-06-01 The objective of this study was to compare the pharmacokinetic profiles of the test product, 300 mg trazodone hydrochloride (HCl) extended-release caplets (containing Contramid®), when administered as a single dose, and the reference product, 100 mg trazodone HCl immediate-release tablets (Apotex Corp), when administered three times daily. For this purpose the rate and extent of absorption of trazodone and formation of m-chlorophenylpiperazine (mCPP) after administration of the two formulations, were compared under fasting conditions.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Oleptro

Condition Name

Condition Name for Oleptro
Intervention Trials
Healthy 3
Sleep Apnea, Obstructive 1
Healthy Subjects 1
Poor Quality Sleep 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Oleptro
Intervention Trials
Disease 2
Depressive Disorder 1
Sleep Apnea Syndromes 1
Depression 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Oleptro

Trials by Country

Trials by Country for Oleptro
Location Trials
United States 19
Canada 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Oleptro
Location Trials
Ohio 2
Arizona 1
Pennsylvania 1
Texas 1
Vermont 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Oleptro

Clinical Trial Phase

Clinical Trial Phase for Oleptro
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
Phase 1 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Oleptro
Clinical Trial Phase Trials
Completed 6
Enrolling by invitation 1
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Oleptro

Sponsor Name

Sponsor Name for Oleptro
Sponsor Trials
Labopharm Inc. 5
Butler Hospital 1
National Institute on Drug Abuse (NIDA) 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Oleptro
Sponsor Trials
Industry 6
U.S. Fed 2
Other 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Johnson and Johnson
Boehringer Ingelheim
Express Scripts
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.